ArticlesOral Ibandronic acid (cas 114084-78-5) versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
-
Add time:08/26/2019 Source:sciencedirect.com
SummaryBackgroundBisphosphonates are routinely used in the treatment of metastatic bone disease from breast cancer to reduce pain and bone destruction. Zoledronic acid given by intravenous infusion has been widely used, but places a substantial logistical burden on both patient and hospital. As a result, the use of oral Ibandronic acid (cas 114084-78-5) has increased, despite the absence of comparative data. In the ZICE trial, we compared oral ibandronic acid with intravenous zoledronic acid for the treatment of metastatic breast cancer to bone.
We also recommend Trading Suppliers and Manufacturers of Ibandronic acid (cas 114084-78-5). Pls Click Website Link as below: cas 114084-78-5 suppliers
Prev:Research paperNovel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation
Next:Eicosanoids as a new class of ocular hypotensive agents. 3. Prostaglandin A2-1-isopropyl ester is the most potent reported hypotensive agent on feline eyes) - 【Back】【Close 】【Print】【Add to favorite 】
-
Health and Chemical more >